Evidence map›Paper›PMID 25742305›Full record

ArticlePloS one2015

Aberrant splicing in transgenes containing introns, exons, and V5 epitopes: lessons from developing an FSHD mouse model expressing a D4Z4 repeat with flanking genomic sequences.

Eugénie Ansseau, Jacqueline S Domire, Lindsay M Wallace, Jocelyn O Eidahl, Susan M Guckes, Carlee R Giesige, Nettie K Pyne, Alexandra Belayew, Scott Q Harper

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Molecular Therapies for Muscular Dystrophies.Current treatment options in neurology · 2018
    Review
  12. Article
  13. Facioscapulohumeral Muscular Dystrophy.Continuum (Minneapolis, Minn.) · 2016
    Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Eugénie AnsseauUniversity of Mons, Research Institute for Health Sciences and Technology, Laboratory of Molecular Biology, Mons, Belgium.
Jacqueline S DomireCenter for Gene Therapy, The Research Institute at Nationwide Children's Hospital, Columbus, OH, United States of America.
Lindsay M WallaceCenter for Gene Therapy, The Research Institute at Nationwide Children's Hospital, Columbus, OH, United States of America.
Jocelyn O EidahlCenter for Gene Therapy, The Research Institute at Nationwide Children's Hospital, Columbus, OH, United States of America.
Susan M GuckesCenter for Gene Therapy, The Research Institute at Nationwide Children's Hospital, Columbus, OH, United States of America.
Carlee R GiesigeCenter for Gene Therapy, The Research Institute at Nationwide Children's Hospital, Columbus, OH, United States of America; Biomedical Sciences Graduate Program, The Ohio State University, Columbus, OH, United States of America.
Nettie K PyneCenter for Gene Therapy, The Research Institute at Nationwide Children's Hospital, Columbus, OH, United States of America.
Alexandra BelayewUniversity of Mons, Research Institute for Health Sciences and Technology, Laboratory of Molecular Biology, Mons, Belgium.
Scott Q HarperCenter for Gene Therapy, The Research Institute at Nationwide Children's Hospital, Columbus, OH, United States of America; Biomedical Sciences Graduate Program, The Ohio State University, Columbus, OH, United States of America; Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH, United States of America.
Nationwide Children's Hospital · USThe Ohio State University · USUniversity of Mons · BE

Funding

DUX4 and the P53 pathway in FSHD pathogenesisR01AR062123 · NIAMS · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI HARPER, SCOTT Q · 2012 to 2016
$1.6M
Training in neuromuscular diseasesT32NS077984 · NINDS · OHIO STATE UNIVERSITY · PI GUTTRIDGE, DENIS C, MENDELL, JERRY ROY · 2012 to 2016
$946k
The Ohio State University Center for Clinical and Translational ScienceTL1TR001069 · NCATS · OHIO STATE UNIVERSITY · PI JACKSON, REBECCA D · 2013 to 2017
$763k
NCATS NIH HHS TL1 TR001069NIAMS NIH HHS 1R01AR062123-01NIAMS NIH HHS R01 AR062123NINDS NIH HHS 1T32NS077984-01NINDS NIH HHS T32 NS077984
6 · The paper itself

Abstract

The DUX4 gene, encoded within D4Z4 repeats on human chromosome 4q35, has recently emerged as a key factor in the pathogenic mechanisms underlying Facioscapulohumeral muscular dystrophy (FSHD). This recognition prompted development of animal models expressing the DUX4 open reading frame (ORF) alone or embedded within D4Z4 repeats. In the first published model, we used adeno-associated viral vectors (AAV) and strong viral control elements (CMV promoter, SV40 poly A) to demonstrate that the DUX4 cDNA caused dose-dependent toxicity in mouse muscles. As a follow-up, we designed a second generation of DUX4-expressing AAV vectors to more faithfully genocopy the FSHD-permissive D4Z4 repeat region located at 4q35. This new vector (called AAV.D4Z4.V5.pLAM) contained the D4Z4/DUX4 promoter region, a V5 epitope-tagged DUX4 ORF, and the natural 3' untranslated region (pLAM) harboring two small introns, DUX4 exons 2 and 3, and the non-canonical poly A signal required for stabilizing DUX4 mRNA in FSHD. AAV.D4Z4.V5.pLAM failed to recapitulate the robust pathology of our first generation vectors following delivery to mouse muscle. We found that the DUX4.V5 junction sequence created an unexpected splice donor in the pre-mRNA that was preferentially utilized to remove the V5 coding sequence and DUX4 stop codon, yielding non-functional DUX4 protein with 55 additional residues on its carboxyl-terminus. Importantly, we further found that aberrant splicing could occur in any expression construct containing a functional splice acceptor and sequences resembling minimal splice donors. Our findings represent an interesting case study with respect to AAV.D4Z4.V5.pLAM, but more broadly serve as a note of caution for designing constructs containing V5 epitope tags and/or transgenes with downstream introns and exons.

Indexed as

ExonsIntronsRNA Splice SitesTransgenesAnimalsDisease Models, AnimalEpitopesMiceMuscular Dystrophy, FacioscapulohumeralEpitopesRNA Splice Sites

Identifiers

PMID25742305
PMCPMC4351184
OpenAlexW1963743402

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.